Residual Neuromuscular Blockade in Cardiac Surgery Patients

Status Withdrawn

Clinical Trial Summary

The purpose of this project is to determine if reversal of neuromuscular blockade in cardiac surgery patients expedites time to extubation in fast track patients.

Clinical Trial Description

Neuromuscular blocking agents are used as part of most general anesthetics to help facilitate tracheal intubation and optimal surgical conditions (Barish et al). These medications cause universal paralysis of patients while unconscious. After most surgeries where extubation is planned, the standard of care is to "reverse" any residual neuromuscular blockade with either anticholinesterase treatment (specifically neostigmine) or sugammadex. Despite adequate reversal, residual neuromuscular blockade is a common problem seen in the post-anesthetic care unit (PACU). It leads to issues of airway obstruction, hypoxemia, respiratory complications including atelectasis and pneumonia and muscle weakness (Brull et al). The investigators posit that these complications are likely amplified in patients who require post-operative intensive care unit admission. In particular, the investigators hypothesize that cardiac surgery patients are at risk. Elective cardiac surgery patients are routinely admitted to the CVICU still intubated and ventilator-dependent immediately following surgery. The goal of uncomplicated cardiac surgery patients (fast track cardiac surgery patients) is to extubate them within 6 hours of ICU arrival. However, standard of care throughout the US does not include reversal of their neuromuscular blockade. By the time these patients meet extubation criteria, most providers believe that the neuromuscular blockade should have worn off and therefore do not administer reversal (Murphy et al). The investigators hypothesize that residual neuromuscular blockade delays time to extubation and increases respiratory complications in fast track cardiac surgery patients. By administering reversal of neuromuscular blockade in patients with a Train Of Four ratio of <0.9 we anticipate that there will be an increase from 60 to 85% of patients being successfully extubated within 6 hours of arrival to the ICU and a decrease in composite respiratory complications. ;

Study Design

Related Conditions & MeSH terms

Delayed Emergence from Anesthesia
Residual Neuromuscular Blockade

Clinical Trial Details

NCT number	NCT03574337
Study type	Interventional
Source	Henry Ford Health System
Contact
Status	Withdrawn
Phase	Phase 4
Start date	August 1, 2018
Completion date	August 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04619225` - Cardiac Output and Recovery Time	N/A
Recruiting	`NCT05992090` - Neuromuscular Blockade Monitoring Using Kine-myography vs Electromyography.
Completed	`NCT02146859` - Predictor of Residual Neuromuscular Blockade in Recovery Room After General Anesthesia
Completed	`NCT03585400` - Validation of the REPS Prediction Tool
Terminated	`NCT01678625` - Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade
Completed	`NCT03417804` - Incidence of Postoperative Residual Neuromuscular Blockade in Portugal
Completed	`NCT03111082` - Incidence of Postoperative Neuromuscular Blockade in Post-Anesthesia Care Unit at Parkland Hospital: Does Size Matter?
Completed	`NCT04244266` - Observational Study in Bariatric Surgery
Completed	`NCT02939911` - Residual Neuromuscular Blockade in Pediatric Anesthesia
Completed	`NCT02660398` - Incidence and Severity of Residual Neuromuscular Blockade	Phase 4
Completed	`NCT03920670` - Comparison of the ToFscan and TetraGraph During Recovery of Neuromuscular Function in the Post Anesthesia Care Unit	N/A
Completed	`NCT01837498` - Reversal of Neuromuscular Blockade in Thoracic Surgical Patients
Completed	`NCT02213848` - Effect of Calcium Chloride on Recovery From Neuromuscular Blockade	N/A
Completed	`NCT04352127` - Visual and Electromyography Assessments in Response to Train-of-Four Stimulation of the Ulnar Nerve	N/A
Completed	`NCT04352140` - Electromyographic and Acceleromyographic Monitoring in Restricted Arm Movement Surgical Setting	N/A
Completed	`NCT04312256` - Thumb vs Great Toe Recovery	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.